The Annual conference of Business Development Department of BEACON Pharmaceuticals Limited (BPL) was held in Bali, Indonesia on 31 st December, 2016 The conference theme was Caring Globally. In the opening speech the Managing Director of BE...
Like-wise number one in Oncology, Beacon Pharmaceuticals Limited is the first company in Bangladesh who is proudly exporting Hepatitis C generic medicine more than 45 countries around the Globe. Under the patient support program Beacon Phar...
Beacon Pharmaceutical has received registration of two more products Prasugrel 5 and 10 in Myanmar. Prasugrel is used for prevent thrombosis (blood clotting). It acts as a platelet inhibitor. Besides Prasugrel, Beacon has registered 20 Prod...
Beacon Pharmaceutical and their Nepal partner, Prime Care International Pvt. Ltd have jointly organized the Annual sales conference 2015 at Coxs Bazar, Bangladesh. Directors of Prime Oncology Manager of Beacon Oncology, Nepal and Hi-officia...
Beacon Pharmaceuticals limited and their Sri Lanka partner, Emerchemie has organized a seminar on targeted cancer Therapy at Hotel Cinnamon Lake Colombo. Dr. Foo Sr. consultant oncology Mount Elizabeth Hospital, Singapore was the key note s...
Daclavir (Daclatasvir) is one of the new direct-acting antiviral drugs that target different steps of the hepatitis C virus (HCV) lifecycle. It is the first-ever approved HCV NS5A replication complex inhibitor, meaning it interferes with a...
